What Vertex Pharmaceuticals is patenting — and where it isn't
Portfolio archetype: Established · steady · 2,193 US patents.
Covers 7 entities: VERTEX PHARMACEUTICALS INCORPORATED, VERTEX PHARMACEUTICALS INC, VERTEX PHARMACEUTICAL INCORPORATED, VERTEX PHARMACEUTICALS (SAN DIEGO) LLC, VERTEX PHARMACEUTICALS (EUROPE) LIMITED, VERTEX PHARMACEUTICALS (CANADA) INCORPORATED, +1 more. US-only.
| Total US patents | 2,193 |
|---|---|
| Granted / Applications | 1,074 / 1,119 |
| Estimated in force | 1,846 |
| Filing span | 1995–2025 |
| Filing momentum | steady — recent-window filings ~111% of the prior window |
Browse the full interactive version, then run the same on any competitor (we resolve every entity it files under — old names, subsidiaries, corporate-form variants — in minutes).
Read the full Vertex Pharmaceuticals report — free ↗ Reveal a competitor's strategy — $29.95 →
Drop your email and we'll send you the link to this free Vertex Pharmaceuticals report — plus a code for your first competitor report.
Where they focus
Closest competitors
Top other assignees in this portfolio's main technology areas. Raw assignee names — a single company may appear under several name-variants.
| Assignee | Areas of activity | US patents |
|---|---|---|
| NOVARTIS AG | Therapeutic Drug Activity · Pharmaceutical Preparations · Heterocyclic Compounds | 4,934 |
| THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | Pharmaceutical Preparations · Therapeutic Drug Activity · Heterocyclic Compounds | 4,902 |
| PFIZER INC | Therapeutic Drug Activity · Heterocyclic Compounds · Pharmaceutical Preparations | 4,093 |
| BRISTOL-MYERS SQUIBB COMPANY | Therapeutic Drug Activity · Heterocyclic Compounds · Pharmaceutical Preparations | 4,050 |
| L'OREAL | Pharmaceutical Preparations · Therapeutic Drug Activity · Heterocyclic Compounds | 3,827 |
| GENENTECH INC | Therapeutic Drug Activity · Pharmaceutical Preparations · Heterocyclic Compounds | 3,741 |
| ALLERGAN INC | Therapeutic Drug Activity · Pharmaceutical Preparations · Heterocyclic Compounds | 3,136 |
| BOEHRINGER INGELHEIM INTERNATIONAL GMBH | Therapeutic Drug Activity · Pharmaceutical Preparations · Heterocyclic Compounds | 3,002 |
Strategic read
For a competitor
The wall sits squarely in small-molecule therapeutics: 1,350 patents in Therapeutic Drug Activity (A61P) reinforced by 295 in Heterocyclic Compounds (C07D) and 215 in Pharmaceutical Preparations (A61K), so any program touching those chemical and indication spaces should map its exposure against this portfolio's claims. With roughly 1,846 estimated in force and steady filing (recent-window filings near 111% of the prior window), the claim coverage is being maintained rather than wound down. Crowded neighbors including Novartis, Pfizer, and Bristol-Myers Squibb in the same CPC areas mean freedom-to-operate analysis here should weigh overlapping prior art alongside this company's own grants.
For an acquirer
Diligence should center on the heavy concentration in Therapeutic Drug Activity (A61P), where 1,350 of 2,193 patents sit — a portfolio whose value tracks the durability of a focused therapeutic area rather than broad diversification. The roughly even split between 1,074 granted and 1,119 pending across a 1995–2025 filing span warrants examining the pending applications' prosecution status and the remaining term on the in-force grants (estimated 1,846). The age-biased citation-impact share of 0.26 should be read against the portfolio's established maturity; examine which families anchor the core franchises and how the supporting Heterocyclic Compounds (C07D) and Pharmaceutical Preparations (A61K) estates protect them.
For a licensee
For a licensee operating in small-molecule drug development, the relevant depth is the 1,350-patent Therapeutic Drug Activity (A61P) cluster plus 295 patents in Heterocyclic Compounds (C07D) and 215 in Pharmaceutical Preparations (A61K), indicating coverage spanning compound, formulation, and indication. Steady momentum — recent filings near 111% of the prior window across a portfolio reaching back to 1995 — suggests the estate is actively maintained rather than legacy-only. Smaller adjacent positions in Genetic Engineering (C12N, 98) and Peptides & Proteins (C07K, 35) are worth examining if your area extends beyond the core chemical space.
More company reports
IBM · Apple · eBay · Nvidia · Novo Nordisk
AI-generated research summary, not legal or investment advice — consult a registered patent attorney before any decision. One of PatentLens.AI's free sample reports — browse all company reports.